Wall Street Upgrades Two Biotech Stocks: STRO Price Target Tripled, ORIC Now a Buy
Wedbush lifts Sutro to $60 on STRO-004 hopes; ORIC upgraded on strong cancer data and big market potential.
/ 1656 items
#XY↓
Elliott Management Takes Significant Stake in Dexcom, Pushes for Board Refresh
Dexcom gains Elliott stake; will add board members and restructure, betting on CGM growth; shares rose 6%.
FDA Slaps Full Clinical Hold on Aardvark’s Hunger Drug for Prader-Willi Syndrome
FDA pauses Aardvark’s PWS drug trials over safety concerns; studies stop, shares fall, talks with FDA ongoing.
FDA Fast-Tracks INmune Bio’s XPro for Early Alzheimer’s Disease
FDA gave Fast Track to INmune Bio’s XPro for early Alzheimer’s, speeding trials of a drug targeting brain inflammation.
REGENXBIO Q1 Earnings: Revenue Miss Overshadows Positive Duchenne Gene Therapy Data
Regenxbio’s DMD gene therapy showed strong results, boosting muscle protein and safety, moving closer to FDA approval.
Biogen Advances Alzheimer’s Drug Diranersen to Phase 3 After It Slashes Tau and Slows Cognitive Decline
Biogen’s diranersen showed robust tau reduction and slowed cognitive decline in early Alzheimer’s Phase 2 trial. Moving to late-stage studies despite missing primary endpoint.